2024-05-152023-03P4Y4M24D2022-020001180262falseP12M2025-09-01P15MP12MP4Y4M24D2020-02P2Y1M6DP1M--12-31P1M2026-08-15Q12020-03P4Y4M24D0001180262us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001180262us-gaap:TreasuryStockMember2021-03-310001180262hlf:TwoThousandEighteenTermLoanBMemberus-gaap:FairValueInputsLevel2Memberhlf:TwoThousandEighteenCreditFacilityMember2020-12-310001180262hlf:ForeignExchangeCurrencyContractsRelatingToIntercompanyManagementFeeHedgesMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-03-310001180262hlf:SecondAmendmentMemberhlf:TwoThousandEighteenCreditFacilityMember2021-01-012021-03-310001180262us-gaap:InterestRateSwapMember2020-12-310001180262us-gaap:FederalFundsEffectiveSwapRateMemberhlf:TwoThousandEighteenCreditFacilityMember2018-08-162018-08-160001180262us-gaap:RetainedEarningsMember2020-01-012020-03-3100011802622020-01-012020-03-310001180262us-gaap:AccumulatedTranslationAdjustmentMember2021-03-310001180262us-gaap:AdditionalPaidInCapitalMember2020-03-310001180262hlf:TwoPointSixTwoFivePercentageConvertibleSeniorNotesDueTwoThousandTwentyFourMember2021-03-310001180262us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueInputsLevel2Memberhlf:ForeignExchangeCurrencyContractsRelatingToInventoryHedgesAndIntercompanyManagementFeeHedgesMember2021-03-310001180262hlf:TwoThousandSeventeenCreditFacilityMemberhlf:TwoThousandSeventeenRevolvingCreditFacilityMember2018-08-162018-08-160001180262hlf:TwoThousandEighteenRevolvingCreditFacilityMember2021-03-310001180262hlf:TwoThousandEighteenTermLoanBMemberhlf:TwoThousandEighteenCreditFacilityMember2020-12-3100011802622020-03-310001180262hlf:SecondAmendmentMemberhlf:TwoThousandEighteenTermLoanAMembersrt:MaximumMemberhlf:TwoThousandEighteenCreditFacilityMember2021-03-310001180262hlf:TwoThousandEighteenTermLoanBMemberhlf:TwoThousandEighteenCreditFacilityMember2021-03-310001180262us-gaap:InterestRateSwapMember2021-03-310001180262hlf:SevenPointTwoFiveZeroPercentageSeniorNotesDueTwoThousandAndTwentySixMember2021-01-012021-03-310001180262us-gaap:RetainedEarningsMember2021-03-310001180262us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310001180262hlf:BrazilianICMSMemberhlf:StateOfSaoPauloMember2016-07-310001180262us-gaap:AdditionalPaidInCapitalMember2019-12-310001180262us-gaap:DesignatedAsHedgingInstrumentMemberhlf:ForeignExchangeCurrencyContractsRelatingToInventoryHedgesAndIntercompanyManagementFeeHedgesMember2021-01-012021-03-310001180262us-gaap:CommonStockMemberhlf:OpenMarketRepurchasePlanMember2021-03-3100011802622019-12-310001180262hlf:SevenPointTwoFiveZeroPercentageSeniorNotesDueTwoThousandAndTwentySixMemberhlf:DebtInstrumentRedemptionPeriodSixMember2020-01-012020-12-310001180262hlf:SevenPointEightSevenFivePercentageSeniorNotesDueTwoThousandAndTwentyFiveMemberus-gaap:DebtInstrumentRedemptionPeriodOneMember2020-01-012020-12-310001180262hlf:SevenPointEightSevenFivePercentageSeniorNotesDueTwoThousandAndTwentyFiveMemberhlf:DebtIssuanceCostsMember2020-06-300001180262country:MX2021-01-012021-03-310001180262hlf:OthersMember2020-01-012020-03-310001180262hlf:TwoThousandTwentyFourConvertibleNotesExceedsThreeFiftyMillionMembersrt:MinimumMemberhlf:TwoThousandEighteenCreditFacilityMember2018-08-160001180262hlf:TwoPointSixTwoFivePercentageConvertibleSeniorNotesDueTwoThousandTwentyFourMember2021-01-012021-03-310001180262us-gaap:StockAppreciationRightsSARSMember2020-01-012020-03-310001180262us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001180262us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2021-03-310001180262hlf:TwoThousandEighteenTermLoanAMemberhlf:TwoThousandEighteenCreditFacilityMember2020-03-192020-03-190001180262us-gaap:StockAppreciationRightsSARSMember2021-01-012021-03-310001180262hlf:SevenPointEightSevenFivePercentageSeniorNotesDueTwoThousandAndTwentyFiveMember2020-05-012020-05-310001180262us-gaap:CommonStockMember2020-03-310001180262us-gaap:FairValueInputsLevel2Memberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMember2020-12-310001180262us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-03-310001180262us-gaap:CommonStockMember2021-01-012021-03-310001180262us-gaap:CashFlowHedgingMembersrt:MaximumMemberus-gaap:ForeignExchangeContractMember2021-01-012021-03-310001180262hlf:TwoThousandEighteenCreditFacilityMemberus-gaap:BaseRateMember2018-08-162018-08-160001180262hlf:SecondAmendmentMemberhlf:TwoThousandEighteenCreditFacilityMember2020-01-012020-03-310001180262hlf:SecondAmendmentMemberus-gaap:EurodollarMemberhlf:TwoThousandEighteenCreditFacilityMemberhlf:TwoThousandEighteenRevolvingCreditFacilityMember2021-01-012021-03-310001180262us-gaap:ForeignExchangeContractMember2021-03-310001180262hlf:PerformanceConditionAwardsMember2021-03-310001180262hlf:BrazilianICMSMember2021-03-310001180262hlf:TwoThousandEighteenCreditFacilityMemberus-gaap:InterestRateSwapMember2020-03-310001180262us-gaap:OtherAssetsMember2021-03-310001180262hlf:TwoThousandEighteenCreditFacilityMember2020-12-310001180262us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001180262hlf:HerbalifeInternationalOfAmericaIncMemberhlf:USFederalTradeCommissionMember2021-01-012021-03-310001180262us-gaap:TreasuryStockMember2020-12-310001180262us-gaap:OtherAssetsMember2020-12-3100011802622021-01-012021-03-3100011802622021-04-270001180262us-gaap:EurodollarMember2018-08-162018-08-160001180262hlf:TwoThousandEighteenTermLoanBMemberus-gaap:FairValueInputsLevel2Memberhlf:TwoThousandEighteenCreditFacilityMember2021-03-310001180262hlf:TwoThousandEighteenCreditFacilityMember2021-03-310001180262hlf:SevenPointTwoFiveZeroPercentageSeniorNotesDueTwoThousandAndTwentySixMember2018-09-300001180262hlf:SevenPointTwoFiveZeroPercentageSeniorNotesDueTwoThousandAndTwentySixMember2020-01-012020-12-310001180262hlf:TwoThousandEighteenCreditFacilityMemberus-gaap:BaseRateMemberhlf:TwoThousandEighteenRevolvingCreditFacilityMember2021-01-012021-03-310001180262us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2021-03-310001180262hlf:TwoThousandEighteenCreditFacilityMemberhlf:TwoThousandEighteenRevolvingCreditFacilityMember2018-08-162018-08-160001180262country:CNus-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-03-310001180262hlf:TwoThousandEighteenTermLoanBMemberhlf:TwoThousandEighteenCreditFacilityMemberus-gaap:BaseRateMember2018-08-162018-08-160001180262hlf:TwoThousandEighteenTermLoanAMemberhlf:TwoThousandEighteenCreditFacilityMember2021-03-310001180262hlf:TwoThousandEighteenTermLoanBMemberhlf:TwoThousandEighteenCreditFacilityMemberhlf:ThirdAmendmentMemberus-gaap:BaseRateMember2021-01-012021-03-310001180262hlf:TwoThousandEighteenCreditFacilityMember2019-12-120001180262hlf:SecondAmendmentMembersrt:MaximumMemberhlf:TwoThousandEighteenCreditFacilityMemberhlf:TwoThousandEighteenRevolvingCreditFacilityMember2021-03-310001180262us-gaap:AdditionalPaidInCapitalMember2020-12-310001180262us-gaap:SellingGeneralAndAdministrativeExpensesMemberhlf:SECAndDOJInvestigationMember2020-12-310001180262hlf:SevenPointEightSevenFivePercentageSeniorNotesDueTwoThousandAndTwentyFiveMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMember2020-01-012020-12-310001180262hlf:SecondAmendmentMembersrt:MinimumMemberhlf:TwoThousandEighteenCreditFacilityMemberhlf:TwoThousandEighteenRevolvingCreditFacilityMember2020-03-190001180262hlf:SevenPointEightSevenFivePercentageSeniorNotesDueTwoThousandAndTwentyFiveMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2020-01-012020-12-310001180262us-gaap:StockAppreciationRightsSARSMember2020-01-012020-12-310001180262hlf:TwoThousandEighteenCreditFacilityMemberus-gaap:InterestRateSwapMember2021-03-310001180262hlf:TwoPointSixTwoFivePercentageConvertibleSeniorNotesDueTwoThousandTwentyFourMemberhlf:DebtIssuanceCostsMember2018-03-310001180262us-gaap:FairValueInputsLevel2Memberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMember2021-03-310001180262hlf:SevenPointEightSevenFivePercentageSeniorNotesDueTwoThousandAndTwentyFiveMember2021-01-012021-03-310001180262srt:MaximumMemberhlf:TwoThousandEighteenCreditFacilityMemberus-gaap:InterestRateSwapMember2020-01-012020-03-310001180262hlf:SevenPointTwoFiveZeroPercentageSeniorNotesDueTwoThousandAndTwentySixMember2021-03-310001180262us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2020-12-310001180262hlf:PrimaryReportingSegmentMember2020-01-012020-03-310001180262hlf:FreestandingDerivativesMember2020-01-012020-12-310001180262us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueInputsLevel2Memberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:InterestRateSwapMember2021-03-310001180262us-gaap:RetainedEarningsMember2020-12-310001180262us-gaap:MexicanTaxAuthorityMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-12-310001180262hlf:SevenPointTwoFiveZeroPercentageSeniorNotesDueTwoThousandAndTwentySixMember2018-08-012018-08-310001180262us-gaap:CostOfSalesMemberhlf:ForeignExchangeCurrencyContractsRelatingToInventoryHedgesMember2021-01-012021-03-310001180262hlf:TwoThousandEighteenTermLoanAMemberus-gaap:FairValueInputsLevel2Memberhlf:TwoThousandEighteenCreditFacilityMember2021-03-310001180262hlf:IcahnPartiesMemberus-gaap:CommonStockMember2021-01-310001180262hlf:TwoThousandEighteenTermLoanAMemberhlf:TwoThousandEighteenCreditFacilityMember2018-08-160001180262us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueInputsLevel2Memberhlf:ForeignExchangeCurrencyContractsRelatingToInventoryHedgesAndIntercompanyManagementFeeHedgesMemberus-gaap:OtherCurrentLiabilitiesMember2020-12-3100011802622021-02-082021-02-090001180262hlf:TwoThousandTwentyFourConvertibleNotesExceedsThreeFiftyMillionMembersrt:MinimumMemberhlf:TwoThousandEighteenCreditFacilityMember2020-03-190001180262hlf:TwoThousandEighteenTermLoanBMemberus-gaap:EurodollarMemberhlf:TwoThousandEighteenCreditFacilityMember2019-12-122019-12-120001180262hlf:TwoThousandEighteenTermLoanAMemberhlf:TwoThousandEighteenCreditFacilityMember2020-12-310001180262us-gaap:AccumulatedTranslationAdjustmentMember2020-03-310001180262country:MX2020-01-012020-03-310001180262us-gaap:CommonStockMember2021-03-310001180262hlf:SECAndDOJInvestigationMember2021-01-012021-03-310001180262us-gaap:CommonStockMember2020-12-310001180262us-gaap:SellingGeneralAndAdministrativeExpensesMemberhlf:SECAndDOJInvestigationMember2019-12-310001180262us-gaap:StockAppreciationRightsSARSMember2021-03-310001180262us-gaap:OtherNoncurrentAssetsMemberhlf:AuditPeriodJanuaryTwoThousandFourteenThroughDecemberTwoThousandFourteenMemberhlf:SouthKoreanCustomsAuthorityMember2021-03-310001180262hlf:BrazilianICMSMemberhlf:StateOfRioDeJaneiroMember2018-09-300001180262us-gaap:CommonStockMemberhlf:OpenMarketRepurchasePlanMember2021-01-012021-03-310001180262hlf:PutativeClassPlaintiffsMember2018-08-232018-08-230001180262country:US2021-01-012021-03-310001180262hlf:PerformanceConditionAwardsMember2020-12-310001180262us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001180262hlf:SevenPointTwoFiveZeroPercentageSeniorNotesDueTwoThousandAndTwentySixMemberus-gaap:DebtInstrumentRedemptionPeriodFourMember2020-01-012020-12-310001180262us-gaap:TreasuryStockMember2019-12-310001180262us-gaap:CommonStockMember2019-12-310001180262hlf:SevenPointTwoFiveZeroPercentageSeniorNotesDueTwoThousandAndTwentySixMember2020-12-310001180262hlf:ForeignExchangeCurrencyContractsRelatingToIntercompanyManagementFeeHedgesMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-03-310001180262us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2021-03-3100011802622021-02-080001180262hlf:TwoThousandEighteenCreditFacilityMember2021-01-012021-03-310001180262hlf:SevenPointTwoFiveZeroPercentageSeniorNotesDueTwoThousandAndTwentySixMemberhlf:DebtIssuanceCostsMember2018-09-300001180262us-gaap:PerformanceSharesMember2021-03-310001180262hlf:TwoThousandTwentyFourConvertibleNotesExceedsThreeFiftyMillionMemberhlf:TwoThousandEighteenTermLoanBMemberhlf:TwoThousandEighteenCreditFacilityMember2021-01-012021-03-310001180262us-gaap:MinistryOfFinanceIndiaMember2021-03-310001180262hlf:SevenPointEightSevenFivePercentageSeniorNotesDueTwoThousandAndTwentyFiveMember2020-05-310001180262hlf:SECAndDOJInvestigationMember2020-09-300001180262hlf:SecondAmendmentMemberhlf:TwoThousandEighteenCreditFacilityMemberus-gaap:BaseRateMemberhlf:TwoThousandEighteenRevolvingCreditFacilityMember2021-01-012021-03-310001180262us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2021-01-012021-03-310001180262hlf:SevenPointTwoFiveZeroPercentageSeniorNotesDueTwoThousandAndTwentySixMemberus-gaap:DebtInstrumentRedemptionPeriodFiveMember2020-01-012020-12-310001180262hlf:TwoPointSixTwoFivePercentageConvertibleSeniorNotesDueTwoThousandTwentyFourMember2018-03-310001180262us-gaap:AdditionalPaidInCapitalMember2021-03-310001180262country:CN2020-01-012020-03-310001180262us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2020-01-012020-03-310001180262us-gaap:RetainedEarningsMember2020-03-310001180262hlf:FreestandingDerivativesMember2021-01-012021-03-310001180262us-gaap:DesignatedAsHedgingInstrumentMemberhlf:ForeignExchangeCurrencyContractsRelatingToInventoryHedgesAndIntercompanyManagementFeeHedgesMember2020-01-012020-03-310001180262us-gaap:FairValueInputsLevel2Member2021-03-310001180262hlf:MarketConditionAwardsMembersrt:MaximumMember2020-12-310001180262hlf:TwoThousandEighteenCreditFacilityMember2020-01-012020-03-310001180262us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2020-12-310001180262us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001180262us-gaap:PendingLitigationMember2018-08-232018-08-230001180262us-gaap:RetainedEarningsMember2021-01-012021-03-310001180262hlf:SecondAmendmentMemberhlf:TwoThousandEighteenTermLoanAMemberus-gaap:EurodollarMemberhlf:TwoThousandEighteenCreditFacilityMember2021-01-012021-03-310001180262srt:MinimumMemberhlf:TwoThousandEighteenCreditFacilityMemberus-gaap:InterestRateSwapMember2020-01-012020-03-310001180262hlf:TwoThousandEighteenTermLoanBMemberhlf:TwoThousandEighteenCreditFacilityMember2018-08-162018-08-160001180262srt:MaximumMemberus-gaap:PerformanceSharesMember2021-03-3100011802622021-02-090001180262hlf:SevenPointEightSevenFivePercentageSeniorNotesDueTwoThousandAndTwentyFiveMembersrt:MaximumMember2020-05-012020-05-310001180262hlf:TwoThousandEighteenCreditFacilityMemberus-gaap:InterestRateSwapMember2020-12-310001180262hlf:SevenPointEightSevenFivePercentageSeniorNotesDueTwoThousandAndTwentyFiveMember2020-01-012020-12-310001180262us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueInputsLevel2Memberhlf:ForeignExchangeCurrencyContractsRelatingToInventoryHedgesAndIntercompanyManagementFeeHedgesMemberus-gaap:OtherCurrentLiabilitiesMember2021-03-310001180262us-gaap:CostOfSalesMemberhlf:ForeignExchangeCurrencyContractsRelatingToInventoryHedgesMember2020-01-012020-03-310001180262srt:MaximumMemberus-gaap:ForeignExchangeForwardMember2021-01-012021-03-310001180262us-gaap:OtherNoncurrentAssetsMemberhlf:SouthKoreanCustomsAuthorityMemberhlf:AuditPeriodJanuaryTwoThousandElevenThroughMayTwoThousandThirteenMember2021-03-310001180262srt:MaximumMemberus-gaap:ForeignExchangeForwardMember2020-01-012020-12-310001180262hlf:SeniorUnsecuredNotesMember2018-08-160001180262srt:MaximumMemberhlf:SevenPointTwoFiveZeroPercentageSeniorNotesDueTwoThousandAndTwentySixMember2018-08-012018-08-310001180262us-gaap:MexicanTaxAuthorityMember2021-03-310001180262us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310001180262hlf:TwoThousandEighteenTermLoanBMemberhlf:TwoThousandEighteenCreditFacilityMemberus-gaap:BaseRateMember2019-12-122019-12-120001180262us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-03-310001180262us-gaap:LondonInterbankOfferedRateLIBORMemberhlf:TwoThousandEighteenCreditFacilityMemberus-gaap:InterestRateSwapMember2020-03-310001180262hlf:TwoThousandEighteenCreditFacilityMember2018-08-160001180262hlf:TwoThousandEighteenCreditFacilityMemberhlf:TwoThousandEighteenRevolvingCreditFacilityMember2018-08-160001180262country:BR2021-03-310001180262hlf:TwoPointSixTwoFivePercentageConvertibleSeniorNotesDueTwoThousandTwentyFourMember2020-01-012020-03-310001180262hlf:TwoThousandEighteenTermLoanAMemberhlf:TwoThousandEighteenCreditFacilityMemberhlf:TwoThousandEighteenRevolvingCreditFacilityMemberus-gaap:BaseRateMember2020-03-192020-03-190001180262us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-12-310001180262hlf:TwoThousandEighteenCreditFacilityMember2020-01-012020-12-310001180262us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2020-12-310001180262srt:MaximumMemberus-gaap:PerformanceSharesMember2020-12-310001180262us-gaap:ForeignExchangeContractMember2020-12-310001180262us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001180262country:US2020-01-012020-03-310001180262hlf:BrazilianICMSMemberhlf:StateOfSaoPauloMember2017-08-310001180262us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2020-01-012020-03-310001180262us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-03-3100011802622020-01-012020-12-310001180262hlf:TwoThousandEighteenTermLoanAMemberhlf:TwoThousandTwentyFourConvertibleNotesExceedsThreeFiftyMillionMemberhlf:TwoThousandEighteenCreditFacilityMember2021-01-012021-03-310001180262hlf:IcahnPartiesMemberus-gaap:CommonStockMember2021-01-012021-01-310001180262us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001180262us-gaap:CommonStockMember2020-01-012020-03-310001180262hlf:TwoThousandEighteenTermLoanBMemberus-gaap:EurodollarMemberhlf:TwoThousandEighteenCreditFacilityMemberhlf:ThirdAmendmentMember2021-01-012021-03-310001180262hlf:PerformanceConditionAwardsMember2021-01-012021-03-310001180262hlf:SevenPointTwoFiveZeroPercentageSeniorNotesDueTwoThousandAndTwentySixMember2018-08-310001180262hlf:SecondAmendmentMemberhlf:TwoThousandEighteenCreditFacilityMember2020-03-190001180262us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001180262hlf:TwoThousandEighteenTermLoanBMemberhlf:TwoThousandEighteenCreditFacilityMember2018-08-160001180262hlf:SecondAmendmentMemberhlf:TwoThousandEighteenTermLoanAMemberhlf:TwoThousandEighteenCreditFacilityMember2021-01-012021-03-310001180262hlf:TwoThousandEighteenTermLoanAMemberus-gaap:FairValueInputsLevel2Memberhlf:TwoThousandEighteenCreditFacilityMember2020-12-310001180262hlf:OthersMember2021-01-012021-03-310001180262us-gaap:TreasuryStockMember2020-03-310001180262us-gaap:RetainedEarningsMember2019-12-310001180262us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-12-310001180262hlf:TwoThousandEighteenTermLoanBMemberus-gaap:EurodollarMemberhlf:TwoThousandEighteenCreditFacilityMember2018-08-162018-08-1600011802622020-12-310001180262hlf:TwoThousandEighteenTermLoanBMemberhlf:TwoThousandEighteenCreditFacilityMember2021-01-012021-03-310001180262hlf:SevenPointEightSevenFivePercentageSeniorNotesDueTwoThousandAndTwentyFiveMember2020-06-300001180262hlf:SecondAmendmentMemberhlf:TwoThousandEighteenTermLoanAMembersrt:MinimumMemberhlf:TwoThousandEighteenCreditFacilityMember2020-03-190001180262hlf:TwoThousandEighteenTermLoanAMemberus-gaap:EurodollarMemberhlf:TwoThousandEighteenCreditFacilityMemberhlf:TwoThousandEighteenRevolvingCreditFacilityMember2020-03-192020-03-190001180262us-gaap:OtherNoncurrentAssetsMemberhlf:AuditPeriodMayTwoThousandThirteenThroughDecemberTwoThousandThirteenMemberhlf:SouthKoreanCustomsAuthorityMember2021-03-310001180262hlf:TwoThousandEighteenCreditFacilityMemberhlf:TwoThousandEighteenRevolvingCreditFacilityMember2021-03-310001180262hlf:TwoPointSixTwoFivePercentageConvertibleSeniorNotesDueTwoThousandTwentyFourMember2018-03-012018-03-310001180262hlf:SevenPointEightSevenFivePercentageSeniorNotesDueTwoThousandAndTwentyFiveMember2021-03-310001180262us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-01-012021-03-310001180262hlf:TwoPointSixTwoFivePercentageConvertibleSeniorNotesDueTwoThousandTwentyFourMember2020-01-012020-12-310001180262us-gaap:FairValueInputsLevel2Member2020-12-310001180262country:CN2021-01-012021-03-310001180262us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueInputsLevel2Memberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:InterestRateSwapMember2020-12-310001180262us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-03-310001180262us-gaap:InterestExpenseMemberus-gaap:InterestRateSwapMember2021-01-012021-03-310001180262hlf:MarketConditionAwardsMembersrt:MaximumMember2021-03-310001180262us-gaap:StockAppreciationRightsSARSMember2020-12-310001180262country:CNus-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-03-310001180262hlf:TwoPointSixTwoFivePercentageConvertibleSeniorNotesDueTwoThousandTwentyFourMember2020-12-310001180262hlf:SevenPointTwoFiveZeroPercentageSeniorNotesDueTwoThousandAndTwentySixMember2020-01-012020-03-310001180262hlf:SevenPointEightSevenFivePercentageSeniorNotesDueTwoThousandAndTwentyFiveMember2020-12-3100011802622021-03-310001180262hlf:PrimaryReportingSegmentMember2021-01-012021-03-310001180262us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-03-310001180262us-gaap:LondonInterbankOfferedRateLIBORMemberhlf:TwoThousandEighteenCreditFacilityMember2018-08-162018-08-16iso4217:USDxbrli:shareshlf:Producthlf:Plaintiffxbrli:purexbrli:shareshlf:Countryiso4217:USDhlf:Dayshlf:Segment

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2021

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission file number: 1-32381

 

HERBALIFE NUTRITION LTD.

(Exact name of registrant as specified in its charter)

 

Cayman Islands

98-0377871

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

P.O. Box 309

Ugland House

Grand Cayman

Cayman Islands

KY1-1104

(Address of principal executive offices)

(Zip code)

 

(213) 745-0500

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class:

Trading Symbol(s):

Name of each exchange on which registered:

Common Shares, par value $0.0005 per share

HLF

New York Stock Exchange

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

 

 

 

 

Non-accelerated filer

Smaller reporting company

 

 

 

 

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  

Number of shares of registrant’s common shares outstanding as of April 27, 2021 was 118,032,879.

 

 


 

TABLE OF CONTENTS

 

 

 

Page No.

 

PART I. FINANCIAL INFORMATION

 

 

 

 

Item 1.

Financial Statements

3

 

Unaudited Condensed Consolidated Balance Sheets

3

 

Unaudited Condensed Consolidated Statements of Income

4

 

Unaudited Condensed Consolidated Statements of Comprehensive Income

5

 

Unaudited Condensed Consolidated Statements of Cash Flows

6

 

Notes to Unaudited Condensed Consolidated Financial Statements

7

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

31

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

50

Item 4.

Controls and Procedures

53

 

 

 

 

PART II. OTHER INFORMATION

 

 

 

 

Item 1.

Legal Proceedings

56

Item 1A.

Risk Factors

56

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

78

Item 3.

Defaults Upon Senior Securities

78

Item 4.

Mine Safety Disclosures

78

Item 5.

Other Information

78

Item 6.

Exhibits

78

 

2


 

PART I. FINANCIAL INFORMATION

Item 1.    Financial Statements

HERBALIFE NUTRITION LTD. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

 

 

March 31,
2021

 

 

December 31,
2020

 

 

 

(in millions, except share and par value amounts)

 

ASSETS

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

611.7

 

 

$

1,045.4

 

Receivables, net of allowance for doubtful accounts

 

 

101.3

 

 

 

83.3

 

Inventories

 

 

509.4

 

 

 

501.4

 

Prepaid expenses and other current assets

 

 

164.5

 

 

 

145.7

 

Total current assets

 

 

1,386.9

 

 

 

1,775.8

 

Property, plant, and equipment, at cost, net of accumulated depreciation and amortization

 

 

389.8

 

 

 

390.2

 

Operating lease right-of-use assets

 

 

224.9

 

 

 

222.8

 

Marketing-related intangibles and other intangible assets, net

 

 

313.2

 

 

 

313.3

 

Goodwill

 

 

97.2

 

 

 

100.5

 

Other assets

 

 

254.8

 

 

 

273.5

 

Total assets

 

$

2,666.8

 

 

$

3,076.1

 

LIABILITIES AND SHAREHOLDERS’ DEFICIT

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

111.2

 

 

$

88.7

 

Royalty overrides

 

 

342.7

 

 

 

358.2

 

Current portion of long-term debt

 

 

24.7

 

 

 

22.9

 

Other current liabilities

 

 

588.6

 

 

 

657.5

 

Total current liabilities

 

 

1,067.2

 

 

 

1,127.3

 

Long-term debt, net of current portion

 

 

2,556.3

 

 

 

2,405.5

 

Non-current operating lease liabilities

 

 

207.5

 

 

 

206.7

 

Other non-current liabilities

 

 

198.1

 

 

 

192.7

 

Total liabilities

 

 

4,029.1

 

 

 

3,932.2

 

Commitments and contingencies

 

 

 

 

 

 

Shareholders’ deficit:

 

 

 

 

 

 

Common shares, $0.0005 par value; 2.0 billion shares authorized; 108.0 million (2021) and 120.1 million (2020) shares outstanding

 

 

0.1

 

 

 

0.1

 

Paid-in capital in excess of par value

 

 

298.7

 

 

 

342.3

 

Accumulated other comprehensive loss

 

 

(205.0

)

 

 

(182.2

)

Accumulated deficit

 

 

(1,127.2

)

 

 

(687.4

)

Treasury stock, at cost, 10.0 million (2021) and 10.0 million (2020) shares

 

 

(328.9

)

 

 

(328.9

)

Total shareholders’ deficit

 

 

(1,362.3

)

 

 

(856.1

)

Total liabilities and shareholders’ deficit

 

$

2,666.8

 

 

$

3,076.1

 

 

See the accompanying notes to unaudited condensed consolidated financial statements.

3


 

HERBALIFE NUTRITION LTD. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

 

 

 

Three Months Ended

 

 

 

March 31,
2021

 

 

March 31,
2020

 

 

 

(in millions, except per share amounts)

 

Net sales

 

$

1,501.6

 

 

$

1,262.4

 

Cost of sales

 

 

314.3

 

 

 

245.7

 

Gross profit

 

 

1,187.3

 

 

 

1,016.7

 

Royalty overrides

 

 

474.0

 

 

 

381.2

 

Selling, general, and administrative expenses

 

 

506.7

 

 

 

549.0

 

Other operating income

 

 

(15.9

)

 

 

(9.1

)

Operating income

 

 

222.5

 

 

 

95.6

 

Interest expense, net

 

 

37.5

 

 

 

25.0

 

Income before income taxes

 

 

185.0

 

 

 

70.6

 

Income taxes

 

 

37.6

 

 

 

25.0

 

Net income

 

$

147.4

 

 

$

45.6

 

Earnings per share:

 

 

 

 

 

 

Basic

 

$

1.36

 

 

$

0.33

 

Diluted

 

$

1.33

 

 

$

0.32

 

Weighted-average shares outstanding:

 

 

 

 

 

 

Basic

 

 

108.4

 

 

 

137.8

 

Diluted

 

 

111.1

 

 

 

140.2

 

 

See the accompanying notes to unaudited condensed consolidated financial statements.

4


 

HERBALIFE NUTRITION LTD. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

 

 

 

Three Months Ended

 

 

 

March 31,
2021

 

 

March 31,
2020

 

 

 

(in millions)

 

Net income

 

$

147.4

 

 

$

45.6

 

Other comprehensive loss:

 

 

 

 

 

 

Foreign currency translation adjustment, net of income taxes of $1.5 and $(2.5) for the three months ended March 31, 2021 and 2020, respectively

 

 

(23.7

)

 

 

(57.1

)

Unrealized gain on derivatives, net of income taxes of $ and $(0.3) for the three months ended March 31, 2021 and 2020, respectively,

 

 

0.9

 

 

 

6.6

 

Total other comprehensive loss

 

 

(22.8

)

 

 

(50.5

)

Total comprehensive income (loss)

 

$

124.6

 

 

$

(4.9

)

 

See the accompanying notes to unaudited condensed consolidated financial statements.

5


 

HERBALIFE NUTRITION LTD. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

 

 

Three Months Ended

 

 

 

March 31,
2021

 

 

March 31,
2020

 

 

 

(in millions)

 

Cash flows from operating activities:

 

 

 

 

 

 

Net income

 

$

147.4

 

 

$

45.6

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

Depreciation and amortization

 

 

26.4

 

 

 

24.2

 

Share-based compensation expenses

 

 

13.3

 

 

 

10.3

 

Non-cash interest expense

 

 

7.1

 

 

 

6.3

 

Deferred income taxes

 

 

8.3

 

 

 

7.4

 

Inventory write-downs

 

 

9.5

 

 

 

3.6

 

Foreign exchange transaction loss

 

 

0.3

 

 

 

8.5

 

Other

 

 

(1.1

)

 

 

(5.0

)

Changes in operating assets and liabilities:

 

 

 

 

 

 

Receivables

 

 

(21.9

)

 

 

(7.8

)

Inventories

 

 

(31.5

)

 

 

(7.4

)

Prepaid expenses and other current assets

 

 

(15.7

)

 

 

(18.1

)

Accounts payable

 

 

23.4

 

 

 

2.9

 

Royalty overrides

 

 

(8.4

)

 

 

(22.9

)

Other current liabilities

 

 

(52.0

)

 

 

92.9

 

Other

 

 

5.0

 

 

 

1.2

 

Net cash provided by operating activities

 

 

110.1

 

 

 

141.7

 

Cash flows from investing activities:

 

 

 

 

 

 

Purchases of property, plant, and equipment

 

 

(33.4

)

 

 

(24.4

)

Other

 

 

 

 

 

0.1

 

Net cash used in investing activities

 

 

(33.4

)

 

 

(24.3

)

Cash flows from financing activities:

 

 

 

 

 

 

Borrowings from senior secured credit facility, net of discount

 

 

270.0

 

 

 

30.2

 

Principal payments on senior secured credit facility and other debt

 

 

(125.2

)

 

 

(5.3

)

Share repurchases

 

 

(645.0

)

 

 

(4.7

)

Other

 

 

1.0

 

 

 

0.8

 

Net cash (used in) provided by financing activities

 

 

(499.2

)

 

 

21.0

 

Effect of exchange rate changes on cash, cash equivalents, and restricted cash

 

 

(11.2

)

 

 

(33.8

)

Net change in cash, cash equivalents, and restricted cash

 

 

(433.7

)

 

 

104.6

 

Cash, cash equivalents, and restricted cash, beginning of period

 

 

1,054.0

 

 

 

847.5

 

Cash, cash equivalents, and restricted cash, end of period

 

$

620.3

 

 

$

952.1

 

 

See the accompanying notes to unaudited condensed consolidated financial statements.

6


 

HERBALIFE NUTRITION LTD. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Organization

Herbalife Nutrition Ltd., a Cayman Islands exempted company with limited liability, was incorporated on April 4, 2002. Herbalife Nutrition Ltd. (and together with its subsidiaries, the “Company” or “Herbalife”) is a global nutrition company that sells weight management; targeted nutrition; energy, sports, and fitness; and outer nutrition products to and through a network of independent members, or Members. In China, the Company sells its products to and through independent service providers and sales representatives to customers and preferred customers, as well as through Company-operated retail platforms when necessary. The Company sells its products in six geographic regions: North America; Mexico; South and Central America; EMEA, which consists of Europe, the Middle East, and Africa; Asia Pacific (excluding China); and China.

2. Significant Accounting Policies

Basis of Presentation

The unaudited condensed consolidated interim financial information of the Company has been prepared in accordance with Article 10 of the Securities and Exchange Commission’s, or SEC, Regulation S-X. Accordingly, as permitted by Article 10 of the SEC’s Regulation S-X, it does not include all of the information required by generally accepted accounting principles in the U.S., or U.S. GAAP, for complete financial statements. The condensed consolidated balance sheet as of December 31, 2020 was derived from the audited financial statements at that date and does not include all the disclosures required by U.S. GAAP, as permitted by Article 10 of the SEC’s Regulation S-X. The Company’s unaudited condensed consolidated financial statements as of March 31, 2021 and for the three months ended March 31, 2021 and 2020 include Herbalife Nutrition Ltd. and all of its direct and indirect subsidiaries. In the opinion of management, the accompanying financial information contains all adjustments, consisting of normal recurring adjustments, necessary to present fairly the Company’s unaudited condensed consolidated financial statements as of March 31, 2021 and for the three months ended March 31, 2021 and 2020. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, or the 2020 10-K. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021.

Recently Adopted Pronouncements

In August 2018, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, No. 2018-14, Compensation — Retirement Benefits — Defined Benefit Plans — General (Subtopic 715-20): Disclosure Framework — Changes to the Disclosure Requirements for Defined Benefit Plans. This ASU removes disclosures that are no longer considered cost beneficial, clarifies the specific requirements of disclosures, and adds disclosure requirements identified as relevant. The amendments in this update are effective for reporting periods beginning after December 15, 2020, with early adoption permitted. The adoption of this guidance during the first quarter of 2021 did not have a material impact on the Company’s condensed consolidated financial statements.

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. This ASU simplifies the accounting for income taxes by eliminating some exceptions to the general approach in the FASB Accounting Standards Codification, or ASC, Topic 740, Income Taxes, and clarifies certain aspects of the existing guidance to promote more consistent application, among other things. The amendments in this update are effective for reporting periods beginning after December 15, 2020, with early adoption permitted. The adoption of this guidance during the first quarter of 2021 did not have a material impact on the Company’s condensed consolidated financial statements.

New Accounting Pronouncements

In August 2020, the FASB issued ASU No. 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This ASU simplifies the accounting for convertible instruments by eliminating certain accounting models, resulting in fewer embedded conversion features being separately recognized from the host contract, and also amends the guidance for derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. Additionally, the amendments in this ASU affect the diluted EPS calculation for convertible instruments. It will require that the effect of potential share settlement be included in the diluted EPS calculation when a convertible instrument may be settled in cash or shares; the if-converted method as opposed to the treasury stock method would be required to calculate diluted EPS for these types of convertible instruments. The amendments in this update are effective for reporting periods beginning after December 15, 2021, with early adoption permitted. The Company is evaluating the potential impact of this adoption on its condensed consolidated financial statements.

7


 

Revenue Recognition

The Company’s net sales consist of product sales. In general, the Company's performance obligation is to transfer its products to its Members. The Company generally recognizes revenue when product is delivered to its Members. For China independent service providers and for third-party importers utilized in certain other countries where sales historically have not been material, the Company recognizes revenue based on the Company’s estimate of when the service provider or third-party importer sells the products because the Company is deemed to be the principal party of these product sales due to the additional selling and operating requirements relating to pricing of products, conducting business with physical locations, and other selling and marketing activities required of the service providers and third-party importers.

The Company’s Members, excluding its China independent service providers, may receive distributor allowances, which are comprised of discounts, rebates, and wholesale commission payments from the Company. Distributor allowances resulting from the Company’s sales of its products to its Members are recorded against net sales because the distributor allowances represent discounts from the suggested retail price.

The Company compensates its sales leader Members with royalty overrides for services rendered relating to the development, retention, and management of their sales organizations. Royalty overrides are payable based on achieved sales volume. Royalty overrides are classified as an operating expense reflecting the services provided to the Company. The Company compensates its China independent service providers and third-party importers utilized in certain other countries for providing marketing, selling, and customer support services. As the Company is the principal party of the product sales as described above, the service fees payable to China independent service providers and the compensation received by third-party importers for the services they provide, which represents the discount provided to them, are recorded in selling, general, and administrative expenses within the Company’s condensed consolidated statements of income.

The Company recognizes revenue when it delivers products to its United States Members; distributor allowances, inclusive of discounts and wholesale commissions, are recorded as a reduction to net sales; and royalty overrides are classified as an operating expense.

Shipping and handling services relating to product sales are recognized as fulfillment activities on the Company’s performance obligation to transfer products and are therefore recorded within net sales as part of product sales and are not considered as separate revenues. Shipping and handling costs paid by the Company are included in cost of sales.

The Company presents sales taxes collected from customers on a net basis.

The Company generally receives the net sales price in cash or through credit card payments at the point of sale. Accounts receivable consist principally of credit card receivables arising from the sale of products to the Company’s Members, and its collection risk is reduced due to geographic dispersion. Credit card receivables were $82.4 million and $65.2 million as of March 31, 2021 and December 31, 2020, respectively. Substantially all credit card receivables were current as of March 31, 2021 and December 31, 2020. The Company recorded $0.3 million and $0.4 million during the three months ended March 31, 2021 and 2020, respectively, in bad-debt expense related to allowances for the Company’s receivables. As of March 31, 2021 and December 31, 2020, the Company’s allowance for doubtful accounts was $3.1 million and $3.3 million, respectively. As of March 31, 2021 and December 31, 2020, the majority of the Company’s total outstanding accounts receivable were current.

The Company records advance sales deposits when payment is received but revenue has not yet been recognized. In the majority of the Company’s markets, advance sales deposits are generally recorded to income when the product is delivered to its Members. Additionally, advance sales deposits also include deferred revenues due to the timing of revenue recognition for products sold through China independent service providers. The estimated deferral period for advance sales deposits is generally within one week. During the three months ended March 31, 2021, the Company recognized substantially all of the revenues that were included within advance sales deposits as of December 31, 2020 and any remaining such balance was not material as of March 31, 2021. Advance sales deposits are included in other current liabilities within the Company’s condensed consolidated balance sheets. See Note 13, Detail of Certain Balance Sheet Accounts, for further information.

In general, if a Member returns product to the Company on a timely basis, they may obtain replacement product from the Company for such returned products. In addition, in general the Company maintains a buyback program pursuant to which it will repurchase products sold to a Member who has decided to leave the business. Allowances for product returns, primarily in connection with the Company’s buyback program, are provided at the time the sale is recorded. This accrual is based upon historical return rates for each country and the relevant return pattern, which reflects anticipated returns to be received over a period of up to 12 months following the original sale. Allowances for product returns were $3.8 million and $3.7 million as of March 31, 2021 and December 31, 2020, respectively.

8


 

The Company’s products are grouped in five principal categories: weight management; targeted nutrition; energy, sports, and fitness; outer nutrition; and literature and promotional items. However, the effect of economic factors on the nature, amount, timing, and uncertainty of revenue recognition and cash flows are similar among all five product categories. The Company defines its operating segments through six geographic regions. The effect of economic factors on the nature, amount, timing, and uncertainty of revenue recognition and cash flows are similar among the geographic regions within the Company’s Primary Reporting Segment. See Note 6, Segment Information, for further information on the Company’s reportable segments and the Company’s presentation of disaggregated revenue by reportable segment.

Distributor Compensation – U.S.

In the U.S., distributor compensation, including Royalty overrides, is capped if the Company does not meet an annual requirement as described in the consent order discussed in more detail in Note 5, Contingencies. On a periodic basis, the Company evaluates if this requirement will be achieved by year end to determine if a cap on distributor compensation will be required, and then determines the appropriate amount of distributor compensation expense, which may vary in each reporting period. As of March 31, 2021, the Company believes that the cap to distributor compensation will not be applicable for the current year.

Other Operating Income

To encourage local investment and operations, governments in various China provinces conduct grant programs. The Company applied for and received several such grants in China. Government grants are recorded into income when a legal right to the grant exists, there is a reasonable assurance that the grant proceeds will be received, and the substantive conditions under which the grants were provided have been met. Generally, these substantive conditions are the Company maintaining operations and paying certain taxes in the relevant province and obtaining government approval by completing an annual application process. The Company believes the continuing obligation with respect to the funds is a general requirement that they are used only for its business in China. The Company recognized government grant income related to its regional headquarters and distribution centers within China of approximately $15.9 million and $9.1 million during the three months ended March 31, 2021 and 2020, respectively, in other operating income within its condensed consolidated statements of income. The Company intends to continue applying for government grants in China when programs are available; however, there is no assurance that the Company will receive grants in future periods.

Restricted Cash

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Company’s condensed consolidated balance sheets that sum to the total of the same such amounts shown in the Company’s condensed consolidated statements of cash flows:

 

 

 

March 31,
2021

 

 

December 31,
2020

 

 

 

(in millions)

 

Cash and cash equivalents

 

$

611.7

 

 

$

1,045.4

 

Restricted cash included in Prepaid expenses and other current assets

 

 

2.5

 

 

 

2.5

 

Restricted cash included in Other assets

 

 

6.1

 

 

 

6.1

 

Total cash, cash equivalents, and restricted cash shown in the statement of cash flows

 

$

620.3

 

 

$

1,054.0

 

 

The majority of the Company’s consolidated restricted cash is held by certain of its foreign entities and consists of cash deposits that are required due to the business operating requirements in those jurisdictions.

COVID-19 Pandemic

During March 2020, the World Health Organization characterized the outbreak of coronavirus disease 2019, or COVID-19, as a pandemic. In response to the spread of COVID-19, certain government agencies and the Company itself have mandated various measures and recommended others, in each to protect the public and the Company’s employees, which have disrupted certain areas of the Company’s business including, but not limited to, distribution and selling activities. Despite the pandemic having a negative impact in certain of the Company’s markets, the Company’s consolidated net sales was higher for the three months ended March 31, 2021 as compared to the same period in 2020. The ultimate extent and magnitude of the impact of COVID-19 is not known and could have a material adverse impact to the Company’s business and future financial condition and results of operations. Management has been and continues to actively monitor the impact of COVID-19 generally and on the Company.

9


 

The Company’s condensed consolidated financial statements presented herein reflect the latest estimates and assumptions made by management that affect the reported amounts of assets and liabilities and related disclosures as of the date of the condensed consolidated financial statements and reported amounts of revenue and expenses during the reporting periods presented. The Company believes it has used reasonable estimates and assumptions to assess the fair values of its goodwill, marketing-related intangible assets, and long-lived assets; assessment of the annual effective tax rate; valuation of deferred income taxes; and the allowance for doubtful accounts. After reviewing historical and forward-looking information, the Company determined there were no impairments required relating to its goodwill, marketing-related intangible assets, and long-lived assets during the three months ended March 31, 2021. 

3. Inventories

Inventories consist primarily of finished goods available for resale. Inventories are stated at lower of cost (primarily on the first-in, first-out basis) and net realizable value.

The following are the major classes of inventory:

 

 

 

March 31,
2021

 

 

December 31,
2020

 

 

 

(in millions)

 

Raw materials

 

$

78.2

 

 

$

80.1

 

Work in process

 

 

7.1

 

 

 

7.9

 

Finished goods

 

 

424.1

 

 

 

413.4

 

Total

 

$

509.4

 

 

$

501.4

 

 

4. Long-Term Debt

Long-term debt consists of the following:

 

 

 

March 31,
2021

 

 

December 31,
2020

 

 

 

(in millions)

 

Borrowings under senior secured credit facility, carrying value

 

$

1,121.7

 

 

$

976.5

 

2.625% convertible senior notes due 2024, carrying value of liability component

 

 

466.8

 

 

 

460.6

 

7.875% senior notes due 2025, carrying value

 

 

593.2

 

 

 

592.9

 

7.250% senior notes due 2026, carrying value

 

 

396.0

 

 

 

395.9

 

Other

 

 

3.3

 

 

 

2.5

 

Total

 

 

2,581.0

 

 

 

2,428.4

 

Less: current portion

 

 

24.7

 

 

 

22.9

 

Long-term portion

 

$

2,556.3

 

 

$

2,405.5

 

 

Senior Secured Credit Facility

On August 16, 2018, the Company entered into a $1.25 billion senior secured credit facility, or the 2018 Credit Facility, consisting of a $250.0 million term loan A, or the 2018 Term Loan A, a $750.0 million term loan B, or the 2018 Term Loan B, and a $250.0 million revolving credit facility, or the 2018 Revolving Credit Facility, with a syndicate of financial institutions as lenders. Prior to the amendment described below, the 2018 Term Loan A and 2018 Revolving Credit Facility both were to mature on August 16, 2023. The 2018 Term Loan B matures upon the earlier of: (i) August 18, 2025; or (ii) December 15, 2023 if the outstanding principal on the 2024 Convertible Notes, as defined below, exceeds $350.0 million and the Company exceeds certain leverage ratios as of that date. All obligations under the 2018 Credit Facility are unconditionally guaranteed by certain direct and indirect wholly-owned subsidiaries of Herbalife Nutrition Ltd. and secured by the equity interests of certain of Herbalife Nutrition Ltd.’s subsidiaries and substantially all of the assets of the domestic loan parties. Also on August 16, 2018, the Company issued $400 million aggregate principal amount of senior unsecured notes, or the 2026 Notes, as described below, and used the proceeds from the 2018 Credit Facility and the 2026 Notes to repay in full the $1,178.1 million outstanding under the Company's previous senior secured credit facility.

The 2018 Term Loan B was issued to the lenders at a 0.25% discount, or $1.9 million. The Company incurred approximately $11.7 million of debt issuance costs in connection with the 2018 Credit Facility. The discount and debt issuance costs are recorded on the Company’s condensed consolidated balance sheet and are being amortized over the life of the 2018 Credit Facility using the effective-interest method.

10


 

On December 12, 2019, the Company amended the 2018 Credit Facility which, among other things, reduced the interest rate for borrowings under the 2018 Term Loan B from either the eurocurrency rate plus a margin of 3.25% or the base rate plus a margin of 2.25% to either the eurocurrency rate plus a margin of 2.75% or the base rate plus a margin of 1.75%. The Company incurred approximately $1.2 million of debt issuance costs in connection with the amendment. For accounting purposes, pursuant to FASB ASC Topic 470, Debt, or ASC 470, this transaction was accounted for as a modification of the 2018 Credit Facility. The debt issuance costs were recognized in interest expense, net within the Company’s condensed consolidated statement of income during the year ended December 31, 2019.

On March 19, 2020, the Company amended the 2018 Credit Facility which, among other things, extended the maturity of both the 2018 Term Loan A and 2018 Revolving Credit Facility to the earlier of: (i) March 19, 2025 or (ii) September 15, 2023 if the outstanding principal on the 2024 Convertible Notes, as defined below, exceeds $350.0 million and the Company exceeds certain leverage ratios as of that date; increased borrowings under the 2018 Term Loan A from $234.4 million to a total of $264.8 million; increased the total available borrowing capacity under 2018 Revolving Credit Facility from $250.0 million to $282.5 million; and reduced the interest rate for borrowings under both the 2018 Term Loan A and 2018 Revolving Credit Facility from either the eurocurrency rate plus a margin of 3.00% or the base rate plus a margin of 2.00% to either the eurocurrency rate plus a margin of 2.50% or the base rate plus a margin of 1.50%. The Company incurred approximately $1.6 million of debt issuance costs in connection with the amendment. For accounting purposes, pursuant to ASC 470, this transaction was accounted for as a modification of the 2018 Credit Facility. Of the $1.6 million of debt issuance costs, approximately $1.1 million was recorded on the Company’s condensed consolidated balance sheet and is being amortized over the life of the 2018 Credit Facility using the effective-interest method, and approximately $0.5 million was recognized in interest expense, net within the Company’s condensed consolidated statement of income during the three months ended March 31, 2020.

On February 10, 2021, the Company amended the 2018 Credit Facility which, among other things, reduced the interest rate for borrowings under the 2018 Term Loan B from either the eurocurrency rate plus a margin of 2.75% or the base rate plus a margin of 1.75% to either the eurocurrency rate plus a margin of 2.50% or the base rate plus a margin of 1.50%. The Company incurred approximately $1.1 million of debt issuance costs in connection with the amendment. For accounting purposes, pursuant to ASC 470, this transaction was accounted for as a modification of the 2018 Credit Facility. The debt issuance costs were recognized in interest expense, net within the Company’s condensed consolidated statement of income during the three months ended March 31, 2021.

Under the 2018 Credit Facility, borrowings under the 2018 Term Loan A, 2018 Term Loan B, and 2018 Revolving Credit Facility all bear interest at either the eurocurrency rate plus a margin of 2.50% or the base rate plus a margin of 1.50%. The eurocurrency rate is based on adjusted LIBOR and is subject to a floor of 0.00%. The base rate represents the highest of the Federal Funds Rate plus 0.50%, one-month adjusted LIBOR plus 1.00%, and the prime rate quoted by The Wall Street Journal, and is subject to a floor of 1.00%. The Company is required to pay a commitment fee on the 2018 Revolving Credit Facility of 0.35% per annum on the undrawn portion of the 2018 Revolving Credit Facility. Interest is due at least quarterly on amounts outstanding under the 2018 Credit Facility.

The 2018 Credit Facility requires the Company to comply with a leverage ratio. The 2018 Credit Facility also contains affirmative and negative covenants customary for financings of this type, including, among other things, limitations or prohibitions on repurchasing common shares, declaring and paying dividends and other distributions, redeeming and repurchasing certain other indebtedness, loans and investments, additional indebtedness, liens, mergers, asset sales and transactions with affiliates. In addition, the 2018 Credit Facility contains customary events of default. As of March 31, 2021 and December 31, 2020, the Company was in compliance with its debt covenants under the 2018 Credit Facility.

The 2018 Term Loan A and 2018 Term Loan B are payable in consecutive quarterly installments which began on December 31, 2018. In addition, beginning in 2020, the Company may be required to make mandatory prepayments towards the 2018 Term Loan B based on the Company’s consolidated leverage ratio and annual excess cash flows as defined under the terms of the 2018 Credit Facility. The Company is also permitted to make voluntary prepayments. Amounts outstanding under the 2018 Term Loan A may be voluntarily prepaid without premium or penalty, subject to customary breakage fees in connection with the prepayment of a eurocurrency loan. Under the amended 2018 Credit Facility, amounts voluntarily prepaid under the 2018 Term Loan B on or before August 10, 2021 will incur a prepayment premium of 1%; thereafter, amounts outstanding under the 2018 Term Loan B may be voluntarily prepaid without premium or penalty, subject to customary breakage fees in connection with the prepayment of a eurocurrency loan. These prepayments, if any, will be applied against remaining quarterly installments owed under the 2018 Term Loan A and 2018 Term Loan B in order of maturity with the remaining principal due upon maturity, unless directed otherwise by the Company. Based on the 2020 consolidated leverage ratio and excess cash flow calculation, both as defined under the terms of the 2018 Credit Facility, the Company will not be required to make a mandatory prepayment in 2021 toward the 2018 Term Loan B.

As of March 31, 2021 and December 31, 2020, the weighted-average interest rate for borrowings under the 2018 Credit Facility was 2.78% and 3.39%, respectively.

11


 

During the three months ended March 31, 2021, the Company borrowed an aggregate amount of $270.0 million under the 2018 Credit Facility and repaid a total amount of $125.2 million on amounts outstanding under the 2018 Credit Facility. During the three months ended March 31, 2020, the Company borrowed an aggregate amount of $30.4 million under the 2018 Credit Facility and repaid a total amount of $5.2 million on amounts outstanding under the 2018 Credit Facility. As of March 31, 2021 and December 31, 2020, the U.S. dollar amount outstanding under the 2018 Credit Facility was $1,129.5 million and $984.7 million, respectively. Of the $1,129.5 million outstanding under the 2018 Credit Facility as of March 31, 2021, $248.3 million was outstanding under the 2018 Term Loan A, $731.2 million was outstanding under the 2018 Term Loan B, and $150.0 million was outstanding under the 2018 Revolving Credit Facility. Of the $984.7 million outstanding under the 2018 Credit Facility as of December 31, 2020, $251.6 million was outstanding under the 2018 Term Loan A and $733.1 million was outstanding under the 2018 Term Loan B. There were no borrowings outstanding under the 2018 Revolving Credit Facility as of December 31, 2020. There were no outstanding foreign currency borrowings under the 2018 Credit Facility as of March 31, 2021 and December 31, 2020.

During the three months ended March 31, 2021 and 2020, the Company recognized $9.3 million and $12.3 million, respectively, of interest expense relating to the 2018 Credit Facility, which included $0.1 million and $0.1 million, respectively, relating to non-cash interest expense relating to the debt discount and $0.5 million and $0.4 million, respectively, relating to amortization of debt issuance costs.

The fair value of the outstanding borrowings on the 2018 Term Loan A is determined by utilizing over-the-counter market quotes for similar instruments, which are considered Level 2 inputs as described in Note 12, Fair Value Measurements. As of March 31, 2021 and December 31, 2020, the carrying value of the 2018 Term Loan A was $247.2 million and $250.5 million, respectively, and the fair value was approximately $247.5 million and $251.9 million, respectively. The fair value of the outstanding borrowings under the 2018 Term Loan B is determined by utilizing over-the-counter market quotes, which are considered Level 2 inputs as described in Note 12, Fair Value Measurements. As of March 31, 2021 and December 31, 2020, the carrying amount of the 2018 Term Loan B was $724.5 million and $726.0 million, respectively, and the fair value was approximately $728.9 million and $734.0 million, respectively. The fair value of the outstanding borrowings on the 2018 Revolving Credit Facility approximated its carrying value of $150.0 million as of March 31, 2021 due to its variable interest rate which reprices frequently and represents floating market rates.

Convertible Senior Notes due 2024

In March 2018, the Company issued $550 million aggregate principal amount of convertible senior notes, or the 2024 Convertible Notes, in a private offering to qualified institutional buyers, pursuant to Rule 144A under the Securities Act of 1933, as amended. The 2024 Convertible Notes are senior unsecured obligations which rank effectively subordinate to any of the Company’s existing and future secured indebtedness, including amounts outstanding under the 2018 Credit Facility, to the extent of the value of the assets securing such indebtedness. The 2024 Convertible Notes pay interest at a rate of 2.625% per annum payable semiannually in arrears on March 15 and September 15 of each year, beginning on September 15, 2018. Unless redeemed, repurchased or converted in accordance with their terms prior to such date, the 2024 Convertible Notes mature on March 15, 2024. Holders of the 2024 Convertible Notes may convert their notes at their option under the following circumstances: (i) during any calendar quarter commencing after the calendar quarter ending June 30, 2018, if the last reported sale price of the Company’s common shares for at least 20 trading days (whether or not consecutive) in a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter exceeds 130% of the conversion price for the 2024 Convertible Notes on each applicable trading day; (ii) during the five business-day period immediately after any five consecutive trading day period, or the measurement period, in which the trading price per $1,000 principal amount of 2024 Convertible Notes for each trading day of that measurement period was less than 98% of the product of the last reported sale price of the Company’s common shares and the conversion rate for the 2024 Convertible Notes for each such day; (iii) if the Company calls the 2024 Convertible Notes for redemption; or (iv) upon the occurrence of specified corporate events. On and after December 15, 2023, holders may convert their 2024 Convertible Notes at any time, regardless of the foregoing circumstances. Upon conversion, the 2024 Convertible Notes will be settled, at the Company’s election, in cash, the Company’s common shares, or a combination thereof, based on the applicable conversion rate at such time. The 2024 Convertible Notes had an initial conversion rate of 16.0056 common shares per $1,000 principal amount of the 2024 Convertible Notes, or an initial conversion price of approximately $62.48 per common share. The conversion rate is subject to adjustment upon the occurrence of certain events and was 16.0467 common shares per $1,000 principal amount of the 2024 Convertible Notes, or a conversion price of approximately $62.32 per common share, as of March 31, 2021.

The Company incurred approximately $12.9 million of issuance costs during the first quarter of 2018 relating to the issuance of the 2024 Convertible Notes. Of the $12.9 million issuance costs incurred, $9.6 million and $3.3 million were recorded as debt issuance costs and additional paid-in capital, respectively, in proportion to the allocation of the proceeds of the 2024 Convertible Notes. The $9.6 million of debt issuance costs, which was recorded as an additional debt discount on the Company’s condensed consolidated balance sheet, are being amortized over the contractual term of the 2024 Convertible Notes using the effective-interest method.

12


 

In March 2018, the $550 million aggregate principal amount of the 2024 Convertible Notes were initially allocated between long-term debt, or liability component, and additional paid-in capital, or equity component, within the Company’s condensed consolidated balance sheet at $410.1 million and $139.9 million, respectively. The liability component was measured using the nonconvertible debt interest rate. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the face value of the 2024 Convertible Notes as a whole. Since the Company must still settle these 2024 Convertible Notes at face value at or prior to maturity, this liability component will be accreted up to its face value resulting in additional non-cash interest expense being recognized within the Company’s condensed consolidated statements of income while the 2024 Convertible Notes remain outstanding. The effective-interest rate on the 2024 Convertible Notes is approximately 8.4% per annum. The equity component is not remeasured as long as it continues to meet the conditions for equity classification.

As of March 31, 2021, the outstanding principal on the 2024 Convertible Notes was $550.0 million, the unamortized debt discount and debt issuance costs were $83.2 million, and the carrying amount of the liability component was $466.8 million, which was recorded to long-term debt within the Company’s condensed consolidated balance sheet. As of December 31, 2020, the outstanding principal on the 2024 Convertible Notes was $550.0 million, the unamortized debt discount and debt issuance costs were $89.4 million, and the carrying amount of the liability component was $460.6 million, which was recorded to long-term debt within the Company’s condensed consolidated balance sheet. The fair value of the liability component relating to the 2024 Convertible Notes was approximately $547.5 million and $541.8 million as of March 31, 2021 and December 31, 2020, respectively.

During the three months ended March 31, 2021 and 2020, the Company recognized $9.7 million and $9.2 million, respectively, of interest expense relating to the 2024 Convertible Notes, which included $5.7 million and $5.3 million, respectively, relating to non-cash interest expense relating to the debt discount and $0.4 million and $0.4 million, respectively, relating to amortization of debt issuance costs.

Senior Notes due 2025

In May 2020, the Company issued $600 million aggregate principal amount of senior notes, or the 2025 Notes, in a private offering in the United States to qualified institutional buyers, pursuant to Rule 144A under the Securities Act of 1933, as amended, and outside the United States pursuant to Regulation S under the Securities Act of 1933, as amended. The 2025 Notes are senior unsecured obligations which rank effectively subordinate to any of the Company’s existing and future secured indebtedness, including amounts outstanding under the 2018 Credit Facility, to the extent of the value of the assets securing such indebtedness. The 2025 Notes pay interest at a rate of 7.875% per annum payable semiannually in arrears on March 1 and September 1 of each year, beginning on March 1, 2021. The 2025 Notes mature on September 1, 2025.

At any time prior to September 1, 2022, the Company may redeem all or part of the 2025 Notes at a redemption price equal to 100% of their principal amount, plus a “make whole” premium as of the redemption date, and accrued and unpaid interest to the redemption date. In addition, at any time prior to September 1, 2022, the Company may redeem up to 40% of the aggregate principal amount of the 2025 Notes with the proceeds of one or more equity offerings, at a redemption price equal to 107.875%, plus accrued and unpaid interest. Furthermore, at any time on or after September 1, 2022, the Company may redeem all or part of the 2025 Notes at the following redemption prices, expressed as percentages of principal amount, plus accrued and unpaid interest thereon to the redemption date, if redeemed during the twelve-month period beginning on September 1 of the years indicated below:

 

 

 

Percentage

 

2022

 

 

103.938

%

2023

 

 

101.969

%

2024 and thereafter

 

 

100.000

%

 

The 2025 Notes contain customary negative covenants, including, among other things, limitations or prohibitions on restricted payments, incurrence of additional indebtedness, liens, mergers, asset sales and transactions with affiliates. In addition, the 2025 Notes contain customary events of default.

The Company incurred approximately $7.9 million of issuance costs during the second quarter of 2020 relating to the issuance of the 2025 Notes. The $7.9 million of debt issuance costs, which was recorded as a debt discount on the Company’s condensed consolidated balance sheet, are being amortized over the contractual term of the 2025 Notes using the effective-interest method.

13


 

As of March 31, 2021, the outstanding principal on the 2025 Notes was $600.0 million, the unamortized debt issuance costs were $6.8 million, and the carrying amount was $593.2 million, which was recorded to long-term debt within the Company’s condensed consolidated balance sheet. As of December 31, 2020, the outstanding principal on the 2025 Notes was $600.0 million, the unamortized debt issuance costs were $7.1 million, and the carrying amount was $592.9 million, which was recorded to long-term debt within the Company’s condensed consolidated balance sheet. The fair value of the 2025 Notes was approximately $654.6 million and $656.3 million as of March 31, 2021 and December 31, 2020, respectively, and was determined by utilizing over-the-counter market quotes and yield curves, which are considered Level 2 inputs as defined in Note 12, Fair Value Measurements.

During the three months ended March 31, 2021, the Company recognized $12.1 million of interest expense relating to the 2025 Notes, which included $0.3 million relating to amortization of debt issuance costs.

Senior Notes due 2026

In August 2018, the Company issued $400 million aggregate principal amount of senior notes, or the 2026 Notes, in a private offering in the United States to qualified institutional buyers, pursuant to Rule 144A under the Securities Act of 1933, as amended, and outside the United States pursuant to Regulation S under the Securities Act of 1933, as amended. The 2026 Notes are senior unsecured obligations which rank effectively subordinate to any of the Company’s existing and future secured indebtedness, including amounts outstanding under the 2018 Credit Facility, to the extent of the value of the assets securing such indebtedness. The 2026 Notes pay interest at a rate of 7.250% per annum payable semiannually in arrears on February 15 and August 15 of each year, beginning on February 15, 2019. The 2026 Notes mature on August 15, 2026.

At any time prior to August 15, 2021, the Company may redeem all or part of the 2026 Notes at a redemption price equal to 100% of their principal amount, plus a “make whole” premium as of the redemption date, and accrued and unpaid interest to the redemption date. In addition, at any time prior to August 15, 2021, the Company may redeem up to 40% of the aggregate principal amount of the 2026 Notes with the proceeds of one or more equity offerings, at a redemption price equal to 107.250%, plus accrued and unpaid interest. Furthermore, at any time on or after August 15, 2021, the Company may redeem all or part of the 2026 Notes at the following redemption prices, expressed as percentages of principal amount, plus accrued and unpaid interest thereon to the redemption date, if redeemed during the twelve-month period beginning on August 15 of the years indicated below:

 

 

 

Percentage

 

2021

 

 

103.625

%

2022

 

 

101.813

%

2023 and thereafter

 

 

100.000

%

 

The 2026 Notes contain customary negative covenants, including, among other things, limitations or prohibitions on restricted payments, incurrence of additional indebtedness, liens, mergers, asset sales and transactions with affiliates. In addition, the 2026 Notes contain customary events of default.

The Company incurred approximately $5.4 million of issuance costs during the third quarter of 2018 relating to the issuance of the 2026 Notes. The $5.4 million of debt issuance costs, which was recorded as a debt discount on the Company’s condensed consolidated balance sheet, are being amortized over the contractual term of the 2026 Notes using the effective-interest method.

As of March 31, 2021, the outstanding principal on the 2026 Notes was $400.0 million, the unamortized debt issuance costs were $4.0 million, and the carrying amount was $396.0 million, which was recorded to long-term debt within the Company’s condensed consolidated balance sheet. As of December 31, 2020, the outstanding principal on the 2026 Notes was $400.0 million, the unamortized debt issuance costs were $4.1 million, and the carrying amount was $395.9 million, which was recorded to long-term debt within the Company’s condensed consolidated balance sheet. The fair value of the 2026 Notes was approximately $420.2 million and $425.0 million as of March 31, 2021 and December 31, 2020, respectively, and was determined by utilizing over-the-counter market quotes and yield curves, which are considered Level 2 inputs as defined in Note 12, Fair Value Measurements.

During the three months ended March 31, 2021 and 2020, the Company recognized $7.4 million and $7.4 million, respectively, of interest expense relating to the 2026 Notes, which included $0.1 million and $0.1 million, respectively, relating to amortization of debt issuance costs.

14


 

Valuation of 2024 Convertible Notes – Level 2 and Level 3 Inputs

In order to determine the initial value of the 2024 Convertible Notes, the Company determined the fair value of the liability component of the 2024 Convertible Notes using two valuation methods. The Company reviewed market data that was available for publicly traded, senior, unsecured nonconvertible corporate bonds issued by companies with similar credit ratings. Assumptions used in the estimate represent what market participants would use in pricing the liability component, including market yields and credit standing to develop the straight debt yield estimate. The Company also used a lattice model, which included inputs such as stock price, the Convertible Note trading price, volatility and dividend yield to estimate the straight debt yield. The Company combined the results of the two valuation methods to determine the fair value of the liability component of the 2024 Convertible Notes. Most of these inputs are primarily considered Level 2 and Level 3 inputs. The Company used similar valuation approaches to determine the subsequent fair value of the liability component only for disclosure purposes, which includes using a lattice model and (1) reviewing market data relating to its 2025 Notes and 2026 Notes and comparable yield curves to determine its straight debt yield estimate, or (2) reviewing market data relating to publicly traded, senior, unsecured nonconvertible corporate bonds issued by companies with similar credit ratings in order to determine its straight debt yield estimate.

Total Debt

The Company’s total interest expense was $38.9 million and $28.9 million for the three months ended March 31, 2021 and 2020, respectively, which was recognized within its condensed consolidated statements of income.

As of March 31, 2021, annual scheduled principal payments of debt were as follows:

 

 

 

Principal Payments

 

 

 

(in millions)

 

2021

 

$

17.8

 

2022

 

 

27.8

 

2023

 

 

27.7

 

2024

 

 

584.2

 

2025

 

 

1,625.3

 

Thereafter

 

 

400.0

 

Total

 

$

2,682.8

 

 

Certain vendors and government agencies may require letters of credit or similar guaranteeing arrangements to be issued or executed. As of March 31, 2021, the Company had $39.5 million of issued but undrawn letters of credit or similar arrangements, which included the Mexico Value Added Tax, or VAT, related letter of credit described in Note 5, Contingencies.

5. Contingencies

The Company is from time to time engaged in routine litigation. The Company regularly reviews all pending litigation matters in which it is involved and establishes reserves deemed appropriate by management for these litigation matters when a probable loss estimate can be made.

The matters described in this Note may take several years to resolve. While the Company believes it has meritorious defenses, it cannot be sure of their ultimate resolution. Although the Company may reserve amounts for certain matters that the Company believes represent the most likely outcome of the resolution of these related disputes, if the Company is incorrect in its assessment, the Company may have to record additional expenses, when it becomes probable that an increased potential liability is warranted.

15


 

Tax Matters

The Mexican Tax Administration Service commenced audits of the Company’s Mexican subsidiaries for the period from January to September 2007 and on May 10, 2013, the Company received an assessment related to that period. This assessment is subject to interest and inflationary adjustments. On July 11, 2013, the Company filed an administrative appeal disputing the assessment. On September 22, 2014, the Mexican Tax Administration Service denied the Company’s administrative appeal. The Company commenced litigation in the Tax Court of Mexico in November 2014 to dispute the assertions made by the Mexican Tax Administration Service in the case. On January 16, 2018, the Tax Court of Mexico issued a verdict upholding the assessment issued by the Mexican Tax Administration Service. On April 16, 2018, the Company filed an appeal of this verdict, and in July 2019, the Circuit Court issued a written verdict upholding the assessment and the judgment of the Tax Court of Mexico. On August 12, 2019, the Company filed an appeal with the Supreme Court of Mexico. On October 16, 2019, the Supreme Court of Mexico refused to hear the Company’s appeal. On October 21, 2019, the Company filed a petition with the Supreme Court of Mexico, asking them to reconsider their previous decision. On April 29, 2020, the Supreme Court of Mexico declined the Company’s second petition and the adverse verdicts of the lower courts became final. The Company will pay the assessed amount in due course. The Company previously recognized a loss of $19.0 million in selling, general, and administrative expenses within the Company’s condensed consolidated statement of income during the year ended December 31, 2019 and has a corresponding accrued liability within its condensed consolidated balance sheet as of March 31, 2021. The Company has an issued but undrawn letter of credit through a bank to guarantee payment of the tax assessment as required, and the letter of credit continued to remain effective as of March 31, 2021.

The Mexican Tax Administration Service has delayed processing VAT refunds for companies operating in Mexico and the Company believes that the process for its Mexico subsidiary to receive VAT refunds may be delayed. As of March 31, 2021, the Company had $21.3 million of Mexico VAT related assets, of which $14.1 million was recognized in other assets and $7.2 million was recognized in prepaid expenses and other current assets within its condensed consolidated balance sheet. This amount relates to VAT payments made over various periods and the Company believes these amounts are recoverable by refund or they may be applied against certain future tax liabilities. Effective January 1, 2019, a tax reform law changed the rules concerning possible use of VAT assets, specifically providing that, for VAT balances generated after December 31, 2018, those balances could not be offset against taxes other than VAT obligations currently due. The Company has not recognized any losses related to these VAT related assets as the Company does not believe a loss is probable.

The Company has received tax assessments for multiple years from the Federal Revenue Office of Brazil related to withholding/contributions based on payments to the Company’s Members. The aggregate combined amount of all these assessments is equivalent to approximately $9.6 million, translated at the March 31, 2021 spot rate. The Company is currently litigating these assessments. The Company has not accrued a loss for the majority of the assessments because the Company does not believe a loss is probable. The Company is currently unable to reasonably estimate the amount of the loss that may result from an unfavorable outcome if additional assessments for other periods were to be issued.

The Company is under examination in several Brazilian states related to ICMS and ICMS-ST taxation. Some of these examinations have resulted in assessments for underpaid tax that the Company has appealed. The State of São Paulo has audited the Company for the 2013 and 2014 tax years. During July 2016, for the State of São Paulo, the Company received an assessment in the aggregate amount of approximately $27.9 million, translated at the March 31, 2021 spot rate, relating to various ICMS issues for its 2013 tax year. In August 2016, the Company filed a first-level administrative appeal which was denied in February 2017. The Company filed a further appeal on March 9, 2017. On March 20, 2018, the Court held a hearing and a verdict was issued in June 2019, remanding the case back to the first-level administrative court. During August 2017, for the State of São Paulo, the Company received an assessment in the aggregate amount of approximately $10.4 million, translated at the March 31, 2021 spot rate, relating to various ICMS issues for its 2014 tax year. In September 2017, the Company filed a first-level administrative appeal for the 2014 tax year. The first-level administrative appeal was denied. The Company filed an appeal at the second-level administrative court in December 2018 and a verdict was issued in April 2019, remanding the case back to the first-level administrative court. During September 2018, for the State of Rio de Janeiro, the Company received an assessment in the aggregate amount of approximately $6.1 million, translated at the March 31, 2021 spot rate, relating to various ICMS-ST issues for its 2016 and 2017 tax years. On November 8, 2018, the Company filed a first-level administrative appeal, which was subsequently denied. On April 5, 2019, the Company appealed this tax assessment to the Administrative Council of Tax Appeals (second-level administrative appeal). The Company has also received other ICMS tax assessments in Brazil. During the fourth quarter of 2015, the Company filed appeals with state judicial courts against three of the assessments. The Company had issued surety bonds in the aggregate amount of $8.7 million, translated at the March 31, 2021 spot rate, to guarantee payment of some of the tax assessments as required while the Company pursues the appeals. In addition, the Company has received several ICMS tax assessments in the aggregate amount of $5.1 million, translated at the March 31, 2021 spot rate, from several other Brazilian states where surety bonds have not been issued. Litigation in all these cases is currently ongoing. The Company also received inquiries from the Brazilian tax authorities relating to various tax matters. The Company has not recognized a loss relating to any of these cases, assessments, and matters as the Company does not believe a loss is probable.

16


 

The Company has received various tax assessments in multiple jurisdictions in India for multiple years from the Indian VAT and Service Tax authorities in an amount equivalent to approximately $14.3 million, translated at the March 31, 2021 spot rate. These assessments are for underpaid VAT and the ability to claim input Service Tax credits. The Company is litigating these cases at the tax administrative level and the tax tribunal levels as it believes it has meritorious defenses. The Company has not recognized a loss as it does not believe a loss is probable. In addition, the Company is under an Indian income tax and transfer pricing audit for the fiscal year ended March 31, 2017. While the income tax audit is continuing, the Company has received a transfer pricing assessment of approximately $13.5 million, translated at the March 31, 2021 spot rate. This assessment is subject to interest and penalties adjustments. The Company currently believes that it is more likely than not that it will be successful in supporting its position relating to this assessment. Accordingly, the Company has not accrued any amounts relating to this matter.

The Korea Customs Service audited the importation activities of Herbalife Korea for the period January 2011 through May 2013. The total assessment for the audit period is $31.3 million, translated at the March 31, 2021 spot rate. The Company has paid the assessment and has recognized these payments in other assets within its condensed consolidated balance sheet as of March 31, 2021. The Company lodged a first-level administrative appeal, which was denied on October 21, 2016. On January 31, 2017, the Company filed a further appeal to the National Tax Tribunal of Korea. In November 2018, the Company received an unfavorable decision from the National Tax Tribunal of Korea. In February 2019, the Company submitted an appeal to the Seoul Administrative Court. On February 17, 2021, the Seoul Administrative Court issued a verdict in favor of the Company. On March 10, 2021, the Korea Customs Service filed an appeal to the High Court against the verdict and the appeal is currently pending. The Korea Customs Service audited the importation activities of Herbalife Korea for the period May 2013 through December 2013. The total assessment for the audit period is $10.2 million, translated at the March 31, 2021 spot rate. The Company has paid the assessment and has recognized this payment in other assets within its condensed consolidated balance sheet as of March 31, 2021. In July 2019, the Company filed an appeal to the National Tax Tribunal of Korea. The Korea Customs Service audited the importation activities of Herbalife Korea for the period January 2014 through December 2014. The total assessment for the audit period is $15.8 million, translated at the March 31, 2021 spot rate. The Company paid the assessment in September 2020 and has recognized this payment in other assets within its condensed consolidated balance sheet as of March 31, 2021. In December 2020, the Company filed an appeal to the National Tax Tribunal of Korea. The Company disagrees with the assertions made in the assessments, as well as the calculation methodology used in the assessments. The Company has not recognized a loss as the Company does not believe a loss is probable.

During the course of 2016, the Company received various questions from the Greek Social Security Agency and on December 29, 2016, the Greek Social Security Agency issued an assessment with respect to Social Security Contributions on Member earnings for the 2006 year. For Social Security issues, the statute of limitations is open for 2007 and later years in Greece. Despite the assessment amount being immaterial, the Company could receive similar assessments covering other years. The Company continues to litigate the assessment. The Company has not recognized a loss as it does not believe a loss is probable. The Company is currently unable to reasonably estimate the amount of the loss that may result from an unfavorable outcome if additional assessments for other periods were to be issued.

During March 2018, the Chinese Customs Service began an audit of the Company’s Chinese importations initially covering the periods 2015 through 2017 and has subsequently expanded its audit. The Company has responded to the initial questions from the Customs Service and the audit is ongoing. The Company believes that it has accrued the appropriate amounts, and at the present time the Company is unable to reasonably estimate the amount of any potential loss in excess of the amount already accrued relating to these matters.

U.S. Federal Trade Commission Consent Order

On July 15, 2016, the Company and the Federal Trade Commission, or the FTC, entered into a proposed Stipulation to Entry of Order for Permanent Injunction and Monetary Judgment, or the Consent Order. The Consent Order was lodged with the U.S. District Court for the Central District of California on July 15, 2016 and became effective on July 25, 2016, or the Effective Date. The Consent Order resolved the FTC’s multi-year investigation of the Company.

17


 

Pursuant to the Consent Order, under which the Company neither admitted nor denied the FTC’s allegations (except as to the Court having jurisdiction over the matter), the Company made, through its wholly-owned subsidiary Herbalife International of America, Inc., a $200 million payment to the FTC. Additionally, the Company implemented and continues to enhance certain existing procedures in the U.S. Among other requirements, the Consent Order requires the Company to categorize all existing and future Members in the U.S. as either “preferred members” – who are simply consumers who only wish to purchase products for their own household use, or “distributors” – who are Members who wish to resell some products or build a sales organization. The Company also agreed to compensate distributors on eligible U.S. sales within their downline organization, which include purchases by preferred members, purchases by a distributor for his or her personal consumption within allowable limits and sales of product by a distributor to his or her customers. The Consent Order also imposes restrictions on a distributor’s ability to open Nutrition Clubs in the United States. The Consent Order subjects the Company to certain audits by an independent compliance auditor for a period of seven years; imposes requirements on the Company regarding compliance certification and record creation and maintenance; and prohibits the Company, its affiliates and its distributors from making misrepresentations and misleading claims regarding, among other things, income and lavish lifestyles. The FTC and the independent compliance auditor have the right to inspect Company records and request additional compliance reports for purposes of conducting audits pursuant to the Consent Order. In September 2016, the Company and the FTC mutually selected Affiliated Monitors, Inc. to serve as the independent compliance auditor. The Company continues to monitor the impact of the Consent Order and, while the Company currently does not expect the settlement to have a long-term and materially adverse impact on its business and its Member base, the Company’s business and its Member base, particularly in the United States, may be negatively impacted. If the Company is unable to comply with the Consent Order then this could result in a material and adverse impact to the Company’s results of operations and financial condition.

Other Matters

As a marketer of foods, dietary and nutritional supplements, and other products that are ingested by consumers or applied to their bodies, the Company has been and is currently subjected to various product liability claims. The effects of these claims to date have not been material to the Company. The Company currently maintains product liability insurance with an annual deductible of $12.5 million.

As previously disclosed, the SEC and the Department of Justice, or DOJ, conducted investigations into the Company’s compliance with the Foreign Corrupt Practices Act, or FCPA, in China. Also, as previously disclosed, the Company conducted its own review and implemented remedial and improvement measures based upon this review, including replacement of certain employees and enhancements of Company policies and procedures in China. The Company cooperated with the SEC and the DOJ and has now reached separate resolutions with each of them.

On August 28, 2020, the SEC accepted the Offer of Settlement and issued an administrative order finding that the Company violated the books and records and internal controls provisions of the FCPA. In addition, on August 28, 2020, the Company and the DOJ separately entered into a court-approved deferred prosecution agreement, or DPA, under which the DOJ deferred criminal prosecution of the Company for a period of three years related to a conspiracy to violate the books and records provisions of the FCPA. Among other things, the Company is required to undertake compliance self-reporting obligations for the three-year terms of the agreements with the SEC and the DOJ. If the Company remains in compliance with the DPA during its three-year term, the deferred charge against the Company will be dismissed with prejudice. In addition, the Company paid the SEC and the DOJ aggregate penalties, disgorgement and prejudgment interest of approximately $123 million in September 2020, where $83 million and $40 million were recognized in selling, general, and administrative expenses within the Company's condensed consolidated statements of income for the years ended December 31, 2020 and 2019, respectively, related to this matter. Any failure to comply with these agreements, or any resulting further government action, could result in a material and adverse impact to the Company’s business, financial condition, and operating results.

On September 18, 2017, the Company and certain of its subsidiaries and Members were named as defendants in a purported class action lawsuit, titled Rodgers, et al. v Herbalife Ltd., et al. and filed in the U.S. District Court for the Southern District of Florida, which alleges violations of Florida’s Deceptive and Unfair Trade Practices statute and federal Racketeer Influenced and Corrupt Organizations statutes, unjust enrichment, and negligent misrepresentation. On August 23, 2018, the Court issued an order transferring the action to the U.S. District Court for the Central District of California as to four of the putative class plaintiffs and ordering the remaining four plaintiffs to arbitration, thereby terminating the Company defendants from the Florida action. The plaintiffs seek damages in an unspecified amount. The Company believes the lawsuit is without merit and will vigorously defend itself against the claims in the lawsuit. The Company is currently unable to reasonably estimate the amount of the loss that may result from an unfavorable outcome.

18


 

6. Segment Information

The Company is a nutrition company that sells a wide range of weight management; targeted nutrition; energy, sports, and fitness; and outer nutrition products. The Company’s products are manufactured by the Company in its Changsha, Hunan, China extraction facility; Suzhou, China facility; Nanjing, China facility; Lake Forest, California facility; and Winston-Salem, North Carolina facility, as well as by third-party providers, and then are sold to Members who consume and sell Herbalife products to retail consumers or other Members. Revenues reflect sales of products by the Company to its Members and are categorized based on geographic location.

As of March 31, 2021, the Company sold products in 95 markets throughout the world and was organized and managed by six geographic regions: North America, Mexico, South and Central America, EMEA, Asia Pacific, and China. The Company defines its operating segments as those geographical operations. The Company aggregates its operating segments, excluding China, into a reporting segment, or the Primary Reporting Segment, as management believes that the Company’s operating segments have similar operating characteristics and similar long-term operating performance. In making this determination, management believes that the operating segments are similar in the nature of the products sold, the product acquisition process, the types of customers to whom products are sold, the methods used to distribute the products, the nature of the regulatory environment, and their economic characteristics. China has been identified as a separate reporting segment as it does not meet the criteria for aggregation. The Company reviews its net sales and contribution margin by operating segment and reviews its assets and capital expenditures on a consolidated basis and not by operating segment. Therefore, net sales and contribution margin are presented by reportable segment and assets and capital expenditures by segment are not presented.

Operating information for the two reportable segments is as follows:

 

 

 

Three Months Ended

 

 

 

March 31,
2021

 

 

March 31,
2020

 

 

 

(in millions)

 

Net sales:

 

 

 

 

 

 

Primary Reporting Segment

 

$

1,332.3

 

 

$

1,072.5

 

China

 

 

169.3

 

 

 

189.9

 

Total net sales

 

$

1,501.6

 

 

$

1,262.4

 

Contribution margin(1):

 

 

 

 

 

 

Primary Reporting Segment

 

$

565.7

 

 

$

467.1

 

China(2)

 

 

147.6

 

 

 

168.4

 

Total contribution margin

 

$

713.3

 

 

$

635.5

 

Selling, general, and administrative expenses(2)

 

 

506.7

 

 

 

549.0

 

Other operating income

 

 

(15.9

)

 

 

(9.1

)

Interest expense, net

 

 

37.5

 

 

 

25.0

 

Income before income taxes

 

 

185.0

 

 

 

70.6

 

Income taxes

 

 

37.6

 

 

 

25.0

 

Net income

 

$

147.4

 

 

$

45.6

 

 

(1) Contribution margin consists of net sales less cost of sales and Royalty overrides. For the China segment, contribution margin does not include service fees to China independent service providers.

(2) Service fees to China independent service providers totaling $95.0 million and $105.7 million for the three months ended March 31, 2021 and 2020, respectively, are included in selling, general, and administrative expenses.

The following table sets forth net sales by geographic area:

 

 

 

Three Months Ended

 

 

 

March 31,
2021

 

 

March 31,
2020

 

 

 

(in millions)

 

Net sales:

 

 

 

 

 

 

United States

 

$

348.6

 

 

$

271.9

 

China

 

 

169.3

 

 

 

189.9

 

Mexico

 

 

118.2

 

 

 

114.9

 

Others

 

 

865.5

 

 

 

685.7

 

Total net sales

 

$

1,501.6

 

 

$

1,262.4

 

 

19


 

7. Share-Based Compensation

The Company has share-based compensation plans, which are more fully described in Note 9, Share-Based Compensation, to the Consolidated Financial Statements included in the 2020 10-K. During the three months ended March 31, 2021, the Company granted restricted stock units subject to service conditions and restricted stock units subject to service and performance conditions.

Share-based compensation expense amounted to $13.3 million and $10.3 million for the three months ended March 31, 2021 and 2020, respectively. As of March 31, 2021, the total unrecognized compensation cost related to all non-vested stock awards was $118.6 million and the related weighted-average period over which it is expected to be recognized is approximately 2.1 years.

The following table summarizes the activity for stock appreciation rights, or SARs, under all share-based compensation plans for the three months ended March 31, 2021:

 

 

 

Number of Awards

 

 

Weighted-Average Exercise Price Per Award

 

 

Weighted-Average Remaining Contractual Term

 

Aggregate Intrinsic Value(1)

 

 

 

(in thousands)

 

 

 

 

 

 

 

(in millions)

 

Outstanding as of December 31, 2020(2)(3)

 

 

3,737

 

 

$

27.23

 

 

4.6 years

 

$

77.8

 

Granted

 

 

 

 

$

 

 

 

 

 

 

Exercised(4)

 

 

(560

)

 

$

29.65

 

 

 

 

 

 

Forfeited

 

 

 

 

$

 

 

 

 

 

 

Outstanding as of March 31, 2021(2)(3)

 

 

3,177

 

 

$

26.81

 

 

4.4 years

 

$

55.8

 

Exercisable as of March 31, 2021(5)

 

 

3,177

 

 

$

26.81

 

 

4.4 years

 

$

55.8

 

Vested and expected to vest as of March 31, 2021

 

 

3,177

 

 

$

26.81

 

 

4.4 years

 

$

55.8

 

 

(1) The intrinsic value is the amount by which the current market value of the underlying stock exceeds the exercise price of the SARs.

(2) Includes less than 0.1 million market condition SARs as of both March 31, 2021 and December 31, 2020.

(3) Includes 0.8 million and 1.1 million performance condition SARs as of March 31, 2021 and December 31, 2020, respectively, which represents the maximum amount that can vest.

(4) Includes 0.3 million performance condition SARs.

(5) Includes less than 0.1 million market condition and 0.8 million performance condition SARs.

There were no SARs granted during the three months ended March 31, 2021 and 2020. The total intrinsic value of SARs exercised during the three months ended March 31, 2021 and 2020 was $13.8 million and $1.6 million, respectively.

The following table summarizes the activities for stock units under all share-based compensation plans for the three months ended March 31, 2021:

 

 

 

Number of Shares

 

 

Weighted-Average Grant Date Fair Value Per Share

 

 

 

(in thousands)

 

 

 

 

Outstanding and nonvested as of December 31, 2020(1)

 

 

3,068

 

 

$

44.01

 

Granted(2)

 

 

1,460

 

 

$

48.32

 

Vested

 

 

(764

)

 

$

43.47

 

Forfeited

 

 

(31

)

 

$

43.82

 

Outstanding and nonvested as of March 31, 2021(1)

 

 

3,733

 

 

$

45.81

 

Expected to vest as of March 31, 2021(3)

 

 

3,263

 

 

$

45.36

 

 

(1) Includes 1,141,028 and 712,596 performance-based stock unit awards as of March 31, 2021 and December 31, 2020, respectively, which represents the maximum amount that can vest.

(2) Includes 428,432 performance-based stock unit awards.

(3) Includes 753,826 performance-based stock unit awards.

The total vesting date fair value of stock units which vested during the three months ended March 31, 2021 and 2020 was $35.5 million and $9.6 million, respectively.

20


 

8. Income Taxes

Income taxes were $37.6 million and $25.0 million for the three months ended March 31, 2021 and 2020, respectively. The effective income tax rate was 20.3% and 35.4% for the three months ended March 31, 2021 and 2020, respectively. The decrease in the effective tax rate for the three months ended March 31, 2021 as compared to the same period in 2020 was primarily due to changes in the geographic mix of the Company’s income and a decrease in expense from discrete events.

As of March 31, 2021, the total amount of unrecognized tax benefits, including related interest and penalties, was $65.1 million. If the total amount of unrecognized tax benefits was recognized, $41.6 million of unrecognized tax benefits, $11.5 million of interest, and $2.1 million of penalties would impact the effective tax rate.

The Company believes that it is reasonably possible that the amount of unrecognized tax benefits could decrease by up to approximately $8.6 million within the next twelve months. Of this possible decrease, $0.8 million would be due to the settlement of audits or resolution of administrative or judicial proceedings. The remaining possible decrease of $7.8 million would be due to the expiration of statute of limitations in various jurisdictions.

9. Derivative Instruments and Hedging Activities

Interest Rate Risk Management

The Company engages in an interest rate hedging strategy for which the hedged transactions are forecasted interest payments on the Company’s 2018 Credit Facility, which are based on variable rates.

During the first quarter of 2020, the Company entered into various interest rate swap agreements with effective dates ranging between February 2020 and March 2020. These agreements collectively provide for the Company to pay interest at a weighted-average fixed rate of 0.98% on aggregate notional amounts of $100.0 million under the 2018 Credit Facility until their respective expiration dates ranging between February 2022 and March 2023, while receiving interest based on LIBOR on the same notional amounts for the same periods. At inception, these swap agreements were designated as cash flow hedges against the variability in certain LIBOR-based borrowings under the 2018 Credit Facility, effectively fixing the interest rate on such notional amounts at a weighted-average effective rate of 3.48%. These hedge relationships qualified as effective under FASB ASC Topic 815, Derivatives and Hedging, or ASC 815, and consequently all changes in the fair value of these interest rate swaps are recorded as a component of accumulated other comprehensive loss within shareholders’ deficit, and are recognized in interest expense, net within the Company’s condensed consolidated statement of income during the period when the hedged item and underlying transaction affect earnings. The fair values of the interest rate swap agreements are based on third-party bank quotes, and as of March 31, 2021 and December 31, 2020, the Company recorded liabilities at fair value of $0.8 million and $1.0 million, respectively, relating to these interest rate swap agreements.

Foreign Currency Instruments

The Company designates certain foreign currency derivatives, primarily comprised of foreign currency forward contracts and option contracts, as freestanding derivatives for which hedge accounting does not apply. The changes in the fair market value of these freestanding derivatives are included in selling, general, and administrative expenses within the Company’s condensed consolidated statements of income. The Company primarily uses freestanding foreign currency derivatives to hedge foreign currency-denominated intercompany transactions and to partially mitigate the impact of foreign currency fluctuations. The fair value of the freestanding foreign currency derivatives is based on third-party quotes. The Company’s foreign currency derivative contracts are generally executed on a monthly basis.

The Company designates as cash flow hedges those foreign currency forward contracts it enters into to hedge forecasted inventory purchases and intercompany management fees that are subject to foreign currency exposures. Forward contracts are used to hedge forecasted inventory purchases over specific months. Changes in the fair value of these forward contracts designated as cash flow hedges, excluding forward points, are recorded as a component of accumulated other comprehensive loss within shareholders’ deficit, and are recognized in cost of sales within the Company's condensed consolidated statement of income during the period which approximates the time the hedged inventory is sold. The Company also hedges forecasted intercompany management fees over specific months. These contracts allow the Company to sell Euros in exchange for U.S. dollars at specified contract rates. Changes in the fair value of these forward contracts designated as cash flow hedges, excluding forward points, are recorded as a component of accumulated other comprehensive loss within shareholders’ deficit, and are recognized in selling, general, and administrative expenses within the Company’s condensed consolidated statement of income during the period when the hedged item and underlying transaction affect earnings. The Company has elected to record changes in the fair value of amounts excluded from the assessment of effectiveness currently in earnings.

21


 

As of March 31, 2021 and December 31, 2020, the aggregate notional amounts of all foreign currency contracts outstanding designated as cash flow hedges were approximately $53.6 million and $56.4 million, respectively. As of March 31, 2021, these outstanding contracts were expected to mature over the next fifteen months. The Company’s derivative financial instruments are recorded on the condensed consolidated balance sheets at fair value based on third-party quotes. As of March 31, 2021, the Company recorded assets at fair value of $0.1 million and liabilities at fair value of $2.6 million relating to all outstanding foreign currency contracts designated as cash flow hedges. As of December 31, 2020, the Company recorded liabilities at fair value of $3.9 million relating to all outstanding foreign currency contracts designated as cash flow hedges. The Company assesses hedge effectiveness at least quarterly and the hedges remained effective as of March 31, 2021 and December 31, 2020.

As of both March 31, 2021 and December 31, 2020, the majority of the Company’s outstanding foreign currency forward contracts had maturity dates of less than twelve months with the majority of freestanding derivatives expiring within one month. As of March 31, 2021, the Company had aggregate notional amounts of approximately $462.2 million of foreign currency contracts, inclusive of freestanding contracts and contracts designated as cash flow hedges.

The following tables summarize the derivative activity during the three months ended March 31, 2021 and 2020 relating to all the Company’s derivatives.

Gains and Losses on Derivative Instruments

The following table summarizes gains (losses) relating to derivative instruments recorded in other comprehensive loss during the three months ended March 31, 2021 and 2020:

 

 

 

Amount of Gain (Loss) Recognized in Other Comprehensive Loss

 

 

 

Three Months Ended

 

 

 

March 31,
2021

 

 

March 31,
2020

 

 

 

(in millions)

 

Derivatives designated as hedging instruments:

 

 

 

 

 

 

Foreign exchange currency contracts relating to inventory and intercompany management fee hedges

 

$

0.5

 

 

$

7.3

 

Interest rate swaps

 

 

 

 

 

(1.2

)

 

As of March 31, 2021, the estimated amount of existing net losses related to cash flow hedges recorded in accumulated other comprehensive loss that are expected to be reclassified into earnings over the next twelve months was $3.4 million.

22


 

The effect of cash flow hedging relationships on the Company’s condensed consolidated statements of income for the three months ended March 31, 2021 and 2020 was as follows:

 

 

 

Location and Amount of Gain (Loss) Recognized in Income on Cash Flow Hedging Relationships

 

 

 

Three Months Ended

 

 

 

March 31,
2021

 

 

March 31,
2020

 

 

 

Cost of sales

 

 

Selling, general, and administrative expenses

 

 

Interest expense, net

 

 

Cost of sales

 

 

Selling, general, and administrative expenses

 

 

Interest expense, net

 

 

 

(in millions)

 

Total amounts presented in the condensed consolidated statements of income

 

$

314.3

 

 

$

506.7

 

 

$

37.5

 

 

$

245.7

 

 

$

549.0

 

 

$

25.0